Siegfried Holding AG

DelveInsight partnered with a pharmaceutical company to evaluate CDMO companies for API and FD development, providing a detailed report on R&D, manufacturing, and commercialization capabilities. The CDMO market, valued at USD 100.02 billion in 2021, is projected to grow to USD 143.87 billion by 2030, driven by demand for innovative therapies. Strategic partnerships and acquisitions, especially during the COVID-19 pandemic, have further fueled market growth. DelveInsight's methodology includes comprehensive evaluation of CDMO capabilities, ensuring clients select the most suitable partners for outsourcing projects.

The global pharmaceutical CDMO market was valued at USD 184.90 billion in 2024 and is projected to reach USD 368.70 billion by 2034, driven by a CAGR of 7.2%. Key players include Pfizer, Biocon Biologics, and Thermo Fisher Scientific. Services offered by CDMOs include antibody production and vaccine development, operating under GMP and cGMP standards. The Asia Pacific region leads with a 42.4% market share, while Europe is expected to grow at a CAGR of 7.7%.

The Pharmaceutical Contract Manufacturing Market is projected to exceed $155 billion in 2024, driven by high in-house drug development costs and varying regulatory requirements. CDMOs like Thermo Fisher Scientific and Samsung Biologics are expanding services to meet demand, offering end-to-end solutions from development to commercial-scale manufacturing. The market report provides revenue forecasts to 2034, regional and national market analyses, and profiles of leading companies.

The pharmaceutical CDMO market is projected to grow from USD 173.2 billion in 2023 to USD 345.6 billion by 2033, driven by the rise in disorder prevalence. Asia Pacific led with a 43% share in 2023, while North America is expected to grow fastest. The API segment dominated in 2023, and the drug segment is forecasted to grow rapidly. Solid dosage forms and pain indications were the largest segments in 2023. Big pharmaceutical companies led the market, with increasing collaborations between CDMOs and pharmaceutical firms. Technological advancements, such as AI and IoT, present opportunities for market growth.

The global small molecule innovator API CDMO market is projected to reach USD 47.14 billion by 2030, growing at a CAGR of 6.53% from 2024. Key drivers include pharmaceutical companies' outsourcing trends, demand for small molecule drugs, and increased clinical trials. The market is segmented by stage type, customer type, therapeutic area, and region, with oncology and Asia Pacific leading in their respective categories.